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Vitamin D Regulation of Cathelicidin 
in the Skin: Toward a Renaissance of 
Vitamin D in Dermatology?
Siegfried Segaert1
1,25-Dihydroxyvitamin D3, the active form of vitamin D, is a major regulator of 
the expression of the cationic antimicrobial peptide cathelicidin, not only in 
monocytes but also in epidermal keratinocytes. The involvement of cathelicidin in 
wound healing and skin diseases as diverse as psoriasis, rosacea, and atopic der-
matitis may create new opportunities for the use of vitamin D in dermatology.
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With epidermal photosynthesis of vita-
min D3 as its main source, vitamin D is 
not a true vitamin for humans. Vitamin 
D3 is biologically inert and needs suc-
cessive hydroxylation by 25-hydroxy-
lase (CYP27A1) in the liver and 1α-
hydroxylase (CYP27B1) in the kidney 
to yield 1α,25-dihydroxyvitamin D3 
[1,25(OH)2D3], also known as calcitri-
ol. In vitamin D target cells, calcitriol 
subsequently activates the vitamin D 
receptor (VDR), resulting in altered 
expression of genes involved in calcium 
metabolism, proliferation, differentia-
tion, apoptosis, and adaptive immunity 
(Reichrath, 2007). Epidermal keratino-
cytes occupy a unique position within 
the vitamin D system because they 
not only possess the full machinery for 
ultraviolet B-dependent photoproduc-
tion of 1,25(OH)2D3 (Vantieghem et 
al., 2006) but also contain VDR and 
respond to 1,25(OH)2D3 with growth 
arrest, differentiation, and changes in 
cytokine expression (Segaert et al., 
1997). Almost two decades ago, this 
property resulted in the successful 
introduction of topical vitamin D ana-
logs totreatpsoriasis (Reichrath, 2007). 
However, other dermatologic indica-
tions for vitamin D derivatives remained 
largely unexplored.
The recent identification of the 
cationic antimicrobial peptide cat-
helicidin as a vitamin D target gene 
(Gombart et al., 2005) and of CYP27B1 
and VDR upregulation in monocytes 
as the link between Toll-like receptor-
2 (TLR-2) activation on the one hand 
and cathelicidin production and intra-
cellular mycobacteria killing on the 
other hand (Liu et al., 2006) created a 
previously unknown and unexpected 
link between innate immunity and the 
vitamin D system. Vitamin D status, as 
determined by its cutaneous photosyn-
thesis, promptly became a plausible 
explanation for increased suscepti-
bility of African-American individu-
als to tuberculosis, seasonal peaking 
of viral infections in winter, and the 
therapeutic effect of phototherapy in 
lupus vulgaris, for which Niels Ryberg 
Finsen received the Nobel prize more 
than a century ago (Liu et al., 2006). 
Whether cutaneous photosynthesis 
of 1,25(OH)2D3 (Vantieghem et al., 
2006) directly enhances innate immu-
nity in the skin by induction of cat-
helicidin in keratinocytes (Schauber 
et al., 2007) or whether skin-photo-
produced vitamin D3 acts via hepatic 
conversion to 25-hydroxyvitamin D3 
to reach target cells, including mono-
cytes and keratinocytes, remains to 
be determined (Segaert and Simonart, 
2008). In addition, the mechanism of 
action of Finsen’s phototherapy is an 
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ongoing matter of debate (Segaert and 
Simonart, 2008).
In contrast to humans and primates, 
cathelicidin expression is not vitamin 
D–regulated in rodents (Gombart et 
al., 2005). The fact that the nocturnal 
life of these animals excludes them 
from vitamin D photosynthesis as an 
evolutionary drive may explain this 
intriguing finding (Liu et al., 2006). 
Interestingly, cats (other nocturnal 
animals) lack cutaneous vitamin D3 
photosynthesis because of insuffi-
cient provitamin D stores in the skin 
(Morris, 1999). During evolution, the 
regulation of cathelicidin expression 
by vitamin D may have appeared in 
parallel with the acquisition of cutane-
ous vitamin D photoproduction as an 
adaptation to sunlight exposure.
Apart from its antimicrobial role in 
innate immunity, cathelicidin exhib-
its biological effects on cell prolifera-
tion and migration and cytokine and 
chemokine production, processes that 
are pivotal in inflammation, angiogen-
esis, and wound repair (Schauber and 
Gallo, 2007). Indeed, changes in vita-
min D metabolism seen in monocytes 
following microbial stimulation of TLR-
2 (Liu et al., 2006) were also observed 
in keratinocytes during wound heal-
ing (Schauber et al., 2007). Following 
skin injury, activation of TLR-2 and the 
cytokine transforming growth factor-β 
(TGF-β) coordinately increased kerati-
nocyte CYP27B1 expression. This per-
mitted 1,25(OH)2D3 biosynthesis, as 
shown indirectly by strong induction 
of 24-hydroxylase, the most vitamin D–
responsive gene known (Schauber et al., 
2007). Locally produced 1,25(OH)2D3 
subsequently induced cathelicidin. 
Furthermore, this sophisticated system 
is maintained by various positive-feed-
back loops, namely, vitamin D–depen-
dent induction of TLR-2 and its cofactor 
CD14 (Schauber et al., 2007) and TGF-β 
(Segaert et al., 1997). The apparent piv-
otal role of the vitamin D–cathelicidin 
system during normal wound healing 
makes it an attractive pharmacologic 
target in developing vitamin D analogs 
to treat conditions that include compro-
mised wound healing. Indeed, defective 
antimicrobial peptide expression has 
been observed in chronic ulcers and 
thermal burns (Zasloff, 2005) and may 
be responsible for retarded healing and 
susceptibility to infection.
Atopic dermatitis is another disease 
with decreased antimicrobial peptide 
expression, accounting for frequent 
cutaneous infections (Zasloff, 2005). 
However, vitamin D analogs, although 
poorly studied, have not been effective 
in atopic dermatitis. Disadvantageous 
vitamin D effects on adaptive immu-
nity—specifically, the T-helper 1 to 
T-helper 2 lymphocyte shift caused by 
keratinocyte induction of thymic stro-
mal lymphopoietin (Li et al., 2006) as 
well as the irritating properties of vita-
min D analogs—probably outweigh the 
beneficial effects of antimicrobial pep-
tide induction.
In contrast, high expression of cathe-
licidin and other antimicrobial peptides 
has been noted in psoriasis (Zasloff, 
2005), an inflammatory skin disease 
in which superinfection is rare. It was 
recently demonstrated that the auto-
immune response in psoriasis is initi-
ated by cathelicidin–DNA complexes 
triggering interferon-α production by 
plasmocytoid dendritic cells (Lande 
et al., 2007). How can we reconcile 
these findings with the effectiveness 
of vitamin D analogs in psoriasis? The 
antipsoriatic effect of active vitamin 
D probably relies primarily on its anti-
proliferative properties in keratinocytes 
(Segaert et al., 1997) or on T-helper 1 
to T-helper 2 skewing during T-helper-
cell differentiation (Li et al., 2006). 
However, this does not exclude catheli-
cidin from being a potentially attractive 
pharmacologic target in this disease.
Intriguingly, lesional skin of rosacea 
patients also contains excessive catheli-
cidin, which is abnormally processed by 
serine proteases to peptides that mimic 
features of the disease in mice (Yamasaki 
et al., 2007). Oral minocycline treatment 
decreases cutaneous protease activity in 
rosacea (Yamasaki et al., 2007), making 
a case for the development of more spe-
cific serine protease inhibitors as topical 
drugs for the disease. Some other ques-
tions can be brought forward in this con-
text. Can photoaggravation of rosacea 
be ascribed to (vitamin D–mediated?) 
induction of cathelicidin in the skin 
(Segaert and Simonart, 2008)? How does 
the poorly understood antirosacea effect 
of metronidazole relate to this newly 
identified role of cathelicidin?
In this issue of the Journal of 
Investigative Dermatology, Schauber 
et al. (2008) explore further the 
mechanisms by which cathelicidin 
and CD14 are induced by calcitriol 
in keratinocytes. The authors deter-
mined that these responses specifi-
cally require the vitamin D receptor 
coactivator SRC3 (steroid receptor 
coactivator 3) and its inherent histone 
acetylation activity (which opens up 
the chromatin, facilitating the access 
of transcription factors such as VDR to 
the transcription start site). Moreover, 
epidermal SRC3 colocalizes with 
cathelicidin in the differentiated super-
ficial layers of the epidermis. The his-
tone deacetylase inhibitors butyrate 
and trichostatin A markedly potentiate 
the vitamin D response in keratino-
cytes on cathelicidin, CD14, and 24-
hydroxylase induction, whereas the 
specific VDR antagonist ZK159522 
counteracts induction of the antimi-
crobial peptide. Translating these find-
ings from the bench to the patient 
raises some interesting thoughts: can 
topical histone deacetylase inhibitors 
be combined with vitamin D analogs to 
increase their therapeutic potential in 
skin diseases such as psoriasis? Is there 
a rationale for the topical application of 
VDR antagonists in diseases with exces-
sive cathelicidin expression such as 
rosacea? Because some vitamin D ana-
logs already exist that owe their selec-
tiveness to the recruitment of specific 
coactivators (Takeyama et al., 1999), 
can a vitamin D analog be designed 
that selectively recruits SRC3 to the 
VDR and is such an agent capable of 
separating effects on antimicrobial pep-
tide induction from effects on calcium 
metabolism, proliferation, and differen-
tiation? Such a drug would be a prom-
ising candidate to treat conditions with 
defective antimicrobial peptide activity, 
such as chronic wounds or atopic der-
|Mechanisms of  vitamin D effects  wound healing.
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matitis (Zasloff, 2005). Vitamin D may 
be making a comeback in dermatology.
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